Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis

The paper presents a detailed algorithm for the treatment and follow-up of patients with recurrent multiple sclerosis and primary progressive multiple sclerosis in the use of ocrelizumab.

Bibliographic Details
Main Authors:	A. N. Boyko, M. V. Davydovskaya, N. V. Khachanova, M. N. Zakharova, N. N. Spirin, E. V. Popova, V. M. Alifirova, Ya. V. Vlasov, S. A. Sivertseva, F. A. Khabirov, M. V. Shumilina, E. P. Evdoshenko
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2019-11-01
Series:	Nevrologiâ, Nejropsihiatriâ, Psihosomatika
Subjects:	ocrelizumab multiple sclerosis recurrent multiple sclerosis primary progressive multiple sclerosis monoclonal antibody
Online Access:	https://nnp.ima-press.net/nnp/article/view/1168

id	doaj-50340e70b9b041c1b92f2411af1f8a4a
record_format	Article
spelling	doaj-50340e70b9b041c1b92f2411af1f8a4a2021-07-29T08:58:40ZrusIMA-PRESS LLCNevrologiâ, Nejropsihiatriâ, Psihosomatika2074-27112310-13422019-11-01113162510.14412/2074-2711-2019-3-16-25885Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosisA. N. Boyko0M. V. Davydovskaya1N. V. Khachanova2M. N. Zakharova3N. N. Spirin4E. V. Popova5V. M. Alifirova6Ya. V. Vlasov7S. A. Sivertseva8F. A. Khabirov9M. V. Shumilina10E. P. Evdoshenko11N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia Federal Center for Cerebrovascular Disease and Stroke, Ministry of Health of RussiaN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaResearch Center of NeurologyYaroslavl State Medical University, Ministry of Health of RussiaCity Clinical Hospital Twenty-Four, Moscow Healthcare DepartmentSiberian State Medical University, Ministry of Health of RussiaSamara State Medical University, Ministry of Health of RussiaOAO «Neftyannik» (Oilman) Primary Healthcare UnitRepublican Clinical and Diagnostic Center for Demyelinating Diseases, Ministry of Health of the Republic of TatarstanCity Clinical Hospital Thirty-One, City Center for Multiple Sclerosis TreatmentCity Clinical Hospital Thirty-One, City Center for Multiple Sclerosis TreatmentThe paper presents a detailed algorithm for the treatment and follow-up of patients with recurrent multiple sclerosis and primary progressive multiple sclerosis in the use of ocrelizumab.https://nnp.ima-press.net/nnp/article/view/1168ocrelizumabmultiple sclerosisrecurrent multiple sclerosisprimary progressive multiple sclerosismonoclonal antibody
collection	DOAJ
language	Russian
format	Article
sources	DOAJ
author	A. N. Boyko M. V. Davydovskaya N. V. Khachanova M. N. Zakharova N. N. Spirin E. V. Popova V. M. Alifirova Ya. V. Vlasov S. A. Sivertseva F. A. Khabirov M. V. Shumilina E. P. Evdoshenko
spellingShingle	A. N. Boyko M. V. Davydovskaya N. V. Khachanova M. N. Zakharova N. N. Spirin E. V. Popova V. M. Alifirova Ya. V. Vlasov S. A. Sivertseva F. A. Khabirov M. V. Shumilina E. P. Evdoshenko Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis Nevrologiâ, Nejropsihiatriâ, Psihosomatika ocrelizumab multiple sclerosis recurrent multiple sclerosis primary progressive multiple sclerosis monoclonal antibody
author_facet	A. N. Boyko M. V. Davydovskaya N. V. Khachanova M. N. Zakharova N. N. Spirin E. V. Popova V. M. Alifirova Ya. V. Vlasov S. A. Sivertseva F. A. Khabirov M. V. Shumilina E. P. Evdoshenko
author_sort	A. N. Boyko
title	Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
title_short	Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
title_full	Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
title_fullStr	Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
title_full_unstemmed	Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
title_sort	clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
publisher	IMA-PRESS LLC
series	Nevrologiâ, Nejropsihiatriâ, Psihosomatika
issn	2074-2711 2310-1342
publishDate	2019-11-01
description	The paper presents a detailed algorithm for the treatment and follow-up of patients with recurrent multiple sclerosis and primary progressive multiple sclerosis in the use of ocrelizumab.
topic	ocrelizumab multiple sclerosis recurrent multiple sclerosis primary progressive multiple sclerosis monoclonal antibody
url	https://nnp.ima-press.net/nnp/article/view/1168
work_keys_str_mv	AT anboyko clinicalrecommendationsfortheuseofocrelizumabinpatientswithmultiplesclerosis AT mvdavydovskaya clinicalrecommendationsfortheuseofocrelizumabinpatientswithmultiplesclerosis AT nvkhachanova clinicalrecommendationsfortheuseofocrelizumabinpatientswithmultiplesclerosis AT mnzakharova clinicalrecommendationsfortheuseofocrelizumabinpatientswithmultiplesclerosis AT nnspirin clinicalrecommendationsfortheuseofocrelizumabinpatientswithmultiplesclerosis AT evpopova clinicalrecommendationsfortheuseofocrelizumabinpatientswithmultiplesclerosis AT vmalifirova clinicalrecommendationsfortheuseofocrelizumabinpatientswithmultiplesclerosis AT yavvlasov clinicalrecommendationsfortheuseofocrelizumabinpatientswithmultiplesclerosis AT sasivertseva clinicalrecommendationsfortheuseofocrelizumabinpatientswithmultiplesclerosis AT fakhabirov clinicalrecommendationsfortheuseofocrelizumabinpatientswithmultiplesclerosis AT mvshumilina clinicalrecommendationsfortheuseofocrelizumabinpatientswithmultiplesclerosis AT epevdoshenko clinicalrecommendationsfortheuseofocrelizumabinpatientswithmultiplesclerosis
_version_	1721250590079582208

Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis

Similar Items